Trials / Terminated
TerminatedNCT03869684
A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of MT-0814 for the Treatment of Patients With Age-Related Macular Degeneration
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Senju Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
Age-related macular degeneration (AMD) is the leading cause of blindness among adults in North America. The current standard of care for patients with exudative ("wet") AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy which must be administered by an injection into the eye every 4-8 weeks. MT-0814 is being developed for the treatment of patients with exudative AMD, and could offer an alternative, safer and less burdensome therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT-0814 | Randomly assigned dose |
| DRUG | Placebo | Placebo manufactured to mimic MT-0814 |
Timeline
- Start date
- 2019-02-25
- Primary completion
- 2020-03-25
- Completion
- 2020-04-24
- First posted
- 2019-03-11
- Last updated
- 2021-04-20
- Results posted
- 2021-04-20
Locations
13 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03869684. Inclusion in this directory is not an endorsement.